Introduction to Australia’s drug accessibility policy and its implications for China
- VernacularTitle:澳大利亚药品可及性政策介绍及对我国的启示
- Author:
Bin DENG
1
;
Ying ZHAO
2
Author Information
1. Dept. of Pharmacy，Union Hospital，Tongji Medical College，Huazhong University of Science and Technology，Wuhan 430022，China;Mater Research Institute，University of Queensland，Brisbane 4102，Australia
2. Dept. of Pharmacy，Union Hospital，Tongji Medical College，Huazhong University of Science and Technology，Wuhan 430022，China
- Publication Type:Journal Article
- Keywords:
drug accessibility;
Pharmaceutical Benefits Scheme;
drug price negotiation;
generic drug policy;
orphan drug
- From:
China Pharmacy
2025;36(7):779-783
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To summarize the effective measures and implementation effects of Australia in improving drug accessibility， and provide reference for the optimization and promotion of drug accessibility policies in China. METHODS By searching the official website of the Australian Federal Government and relevant literature， this study introduced Australia’s practical experiences in the Pharmaceutical Benefits Scheme （PBS）， drug registration and PBS access， drug pricing and procurement policies， generic drug price competition and disclosure， and orphan drug registration and approval policies. It summarized the effective measures taken by the federal government to improve drug accessibility and control drug expenditure. RESULTS & CONCLUSIONS The good management collaboration mechanism， flexible drug price negotiation system， and comprehensive drug accessibility policy support system of the Australian health system have maintained a good balance between drug accessibility， patient burden， and government subsidies in the long run， effectively ensuring the accessibility of Australian drugs. It is recommended that our country strengthen policy coordination and departmental cooperation in terms of drug accessibility， optimize the registration and accelerated approval process for new drugs， improve the price management and negotiation mechanism， and establish a comprehensive drug accessibility support system.
